Skip to main content

Advertisement

SpringerLink
Log in

The value of COX-2 expression in the prognostic parameters of invasive ductal carcinoma of the breast

  • Original Paper
  • Published:
Medical Oncology Aims and scope Submit manuscript

Abstract

Cyclooxygenase is an enzyme that changes the immune response to malign cells and catalyzes prostaglandins that may have an impact on cell proliferation. The purpose of this study was to examine the relation between established clinicopathological parameters in breast carcinomas and COX-2 protein expression. COX-2, estrogen receptor (ER), progesterone receptor (PR) and c-erB-2 primary antibodies were assessed in the slides prepared from the paraffin blocks of 62 invasive ductal carcinoma cases. The relation between ER, PR, and c-erbB-2 positivity, histological grade, nuclear grade, lymphovascular invasion, tumor diameter, lymph node positivity, metastasis, and age were evaluated. The results were analyzed statistically. Cytoplasmic COX-2 expression was seen in 75.8% of all breast carcinomas. In both univariate and multivariate logistic regression analysis, there was a positive correlation between COX-2 expression and negative ER status, respectively (P = 0.0173) (P = 0.016). There was any statistically significant relation between PR positivity, c-erbB-2 positivity, histological grade, nuclear grade, lymphovascular invasion, tumor diameter, lymph node positivity, metastasis, and age (P ≥ 0.05). Given that there was found a statistically significant relation between COX-2 expression and negative ER status, which is considered a poor prognostic parameter, suggests that COX-2 expression can have a place among the other prognostic parameters of breast carcinoma.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Denkert C, Winzer KJ, Müler BM, et al. Elevated expression of cyclooxygenase-2 is a negative prognostic factor for disease free survival and overall survival in patients with breast carcinoma. Cancer. 2003;97:2978–87.

    Article  PubMed  CAS  Google Scholar 

  2. Perrone G, Santini D, Vincenzi B, et al. COX-2 expression in DCIS: correlation with VEGF, HER-2/neu, prognostic molecular markers and clinicopathological features. Histopathology. 2005;46:561–8.

    Article  PubMed  CAS  Google Scholar 

  3. Fadden DW, Riggs DR, Jackson BJ, Cunningham C. Additive effect of COX-1 and COX-2 inhibition on breast cancer in vitro. Int J Oncol. 2006;29:1019–23.

    Google Scholar 

  4. Tan KB, Yong WP, Putti TC. Cyclooxygenase-2 expression: a potential prognostic and predictive marker for high-grade ductal carcinoma in situ of breast. Histopathology. 2004;44:24–8.

    Article  PubMed  Google Scholar 

  5. Soslow AS, Dannenberg AJ, Rush D, et al. COX-2 is expressed in human pulmonary, colonic, and mammary tumors. Cancer. 2000;89:2637–45.

    Article  PubMed  CAS  Google Scholar 

  6. Yiu GK, Toker A. NFAT induces breast cancer cell invasion by promoting the induction of cyclooxygenase-2. J Biol Chem. 2006;281:12210–7.

    Article  PubMed  CAS  Google Scholar 

  7. Gallicchio L, McSorley MA, Newschaffer CJ, et al. Nonsteroidal antiinflammatory drugs, cyclooxygenase polymorphisms, and risk of developing breast carcinoma among women with benign breast disease. Cancer. 2006;106:1443–52.

    Article  PubMed  CAS  Google Scholar 

  8. Barnes N, Haywood P, Flint P, Knox WF, Bundred NJ. Survivin expression in in situ and invasive breast cancer relates to COX-2 expression and DCIS recurrence. Br J Cancer. 2006;94:253–8.

    Article  PubMed  CAS  Google Scholar 

  9. Howe LR, Chang SH, Tolle KC, et al. HER-2/neu-induced mammary tumorigenesis and angiogenesis are reduced in cyclooxygenase-2 knockout mice. Cancer Res. 2005;65:10113–9.

    Article  PubMed  CAS  Google Scholar 

  10. Howe LR. Cyclooxygenase/prostaglandin signaling and breast cancer. Breast Cancer Res. 2007;9:210.

    Article  PubMed  Google Scholar 

  11. Nakopoulou L, Mylona E, Papadaki I, Kapranou A, Giannopoulou I. Overexpression of cyclooxygenase-2 is associated with a favorable prognostic phenotype in breast carcinoma. Pathobiology. 2005;72:241–9.

    Article  PubMed  CAS  Google Scholar 

  12. Watson J, Chuah SY. Techniques for primary culture of human breast cancer cells and measurement of their prostaglandin secretion. Clin Sci. 1992;83:347–52.

    PubMed  CAS  Google Scholar 

  13. Fulton AM, Zhang SZ, Chong YC. Role of the prostaglandin E2 receptor in mammary tumor metastasis. Cancer Res. 1991;51:2047–50.

    PubMed  CAS  Google Scholar 

  14. Liu XH, Rose DP. Differential expression and regulation of cyclooxygenase-1 in two human breast cancer cell lines. Cancer Res. 1996;56:5125–7.

    PubMed  CAS  Google Scholar 

  15. Rosai J. Rosai and Ackerman’s surgical pathology. In: Rosai J, editor. Breast. Philadelphia: Mosby Year Book; 2004. p. 1763–876.

    Google Scholar 

  16. Leo C, Faber S, Hentschel B, Höckel M, Horn LC. The status of cyclooxygenase-2 expression in ductal carcinoma in situ lesions and invasive breast cancer correlates to cyclooxygenase-2 expression in normal breast tissue. Ann Diagn Pathol. 2006;10:327–32.

    Article  PubMed  Google Scholar 

  17. Mohammad AM, Abdel HA, Abdel W, Ahmed AM, Wael T, Einman G. Expression of cyclooxygenase-2 and 12-lipoxygenase in human breast cancer and their relationship with HER-2/neu and hormonal receptors: impact on prognosis and therapy. Indian J Cancer. 2006;43:163–8.

    Article  PubMed  CAS  Google Scholar 

  18. Cho MH, Yoon JH, Jaegal YJ, et al. Expression of cyclooxygenase-2 in breast carcinogenesis and its relation to HER-2/neu and p53 protein expression in invasive ductal carcinoma. Breast. 2006;15:390–8.

    Article  PubMed  CAS  Google Scholar 

  19. Oliviera VM, Piato S, Silva ALG. Correlation of cyclooxygenase-2 and aromatase immunohistochemical expression in invasive ductal carcinoma, ductal carcinoma in situ, and adjacent normal epithelium. Breast Cancer Res Treat. 2006;95:235–41.

    Article  Google Scholar 

  20. Costa C, Soares R, Reis-Filho JS, Leitao D, Amendoiera I, Schmitt FC. Cyclo-oxygenase 2 expression is associated with angiogenesis and lymph node metastasis in human breast cancer. J Clin Pathol. 2002;55:429–34.

    Article  PubMed  CAS  Google Scholar 

  21. Ristimaki A, Sivula A, Lundin M, et al. Prognostic significance of elevated cyclooxygenase-2 expression in breast cancer. Cancer Res. 2002;62:632–5.

    PubMed  CAS  Google Scholar 

  22. Nassar A, Radhakrishnan A, Cabrero IA, Cotsonis G, Cohen C. COX-2 expression in invasive breast cancer correlation with prognostic parameters and outcome. Appl Immunohistochem Mol Morphol. 2007;15:255–9.

    Article  PubMed  CAS  Google Scholar 

  23. Bundred NJ, Barnes NLP. Potential use of COX-2-aromatase inhibitor combinations in breast cancer. Br J Cancer. 2005;93:S10–5.

    Article  PubMed  CAS  Google Scholar 

  24. Witton CJ, Hawe SJK, Cooke TJ, Bartlett JM. Cyclooxygenase.2 (COX2) expression is associated with poor outcome in ER-negative, but not ER-positive, breast cancer. Histopathology. 2004;45:47–54.

    Article  PubMed  CAS  Google Scholar 

  25. Robertson FM, Mallery SR, Bergdall-Costell VK, et al. Cyclooxygenase-2 directly induces MCF-7 breast tumor cells to develop into exponentially growing, highly angiogenic and regionally invasive human ductal carcinoma xenografts. Anticancer Res. 2007;27:719–27.

    PubMed  CAS  Google Scholar 

  26. Roche-Nagle G, Connolly EM, Eng M, Bouchier-Hayes DJ, Harmey JH. Antimetastatic activity of a cyclooxygenase-2 inhibitor. Br J Cancer. 2004;91:359–65.

    PubMed  CAS  Google Scholar 

  27. Subbaramaiah K, Norton L, Gerald W, Dannenberg AJ. Cyclooxygenase-2: a target for the prevention and treatment of breast cancer. Endocr Relat Cancer. 2001;8:97–114.

    Article  PubMed  Google Scholar 

  28. Boland GP, Butt IS, Prasad R, Knox WF, Bundred NJ. COX-2 expression is associated with an aggressive phenotype in ductal carcinoma in situ. Br J Cancer. 2004;90:423–9.

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. General Surgery Department, Kartal Research and Education Hospital, Istanbul, Turkey

    Nagehan Ozdemir Barısık, Sevinc Hallac Keser, Aylin Ege Gul, Sibel Sensu, Nilufer Onak Kandemir & Nimet Karadayı

  2. Pathology Department, Kartal Research and Education Hospital, Petrol-is mh. Sh Dursun Bakan Sk. Hilal Sit. A Blok D:21, 34862, Kartal, Istanbul, Turkey

    Hasan Fehmi Kucuk

  3. Oncology Department, Kartal Research and Education Hospital, Istanbul, Turkey

    Mahmut Gumus

Authors
  1. Nagehan Ozdemir Barısık
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Sevinc Hallac Keser
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Aylin Ege Gul
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Sibel Sensu
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Nilufer Onak Kandemir
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Hasan Fehmi Kucuk
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Mahmut Gumus
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Nimet Karadayı
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Nagehan Ozdemir Barısık.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Barısık, N.O., Keser, S.H., Gul, A.E. et al. The value of COX-2 expression in the prognostic parameters of invasive ductal carcinoma of the breast. Med Oncol 28, 703–708 (2011). https://doi.org/10.1007/s12032-010-9503-6

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12032-010-9503-6

Keywords

Search

Navigation